GSK Inks “Transformational” Licensing Agreement With Onco Therapies To Extend Reach In Emerging Markets
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal also extends GSK’s interest in branded generics.
You may also be interested in...
GSK/Aspen Deal Indicates Rising Interest In Emerging Markets Beyond ‘BRIC’
Aspen gains eight specialist medicines and German manufacturing facility from GlaxoSmithKline:
GSK/Aspen Deal Indicates Rising Interest In Emerging Markets Beyond ‘BRIC’
Aspen gains eight specialist medicines and German manufacturing facility from GlaxoSmithKline:
Pharma's Strategic Divide: Focus or Diversify
It looks like the biggest strategic gulf in the industry: focus or diversify? If the CEO thinks he can't rely on R&D to grow his way out of the industry's revenue hole, get ready to live alongside generics and OTC businesses--though he'll downplay to investors the risks of managing different businesses by stressing the commonalities with the core branded efforts and probably won't move into wholly non-pharma businesses. If he's still committed to R&D--get ready for diversification of other sorts, and some pretty clever financial tactics.